Utility of quetiapine in tardive dyskinesia;Utilidad de la quetiapina en la discinesia tardía

Actas Espanolas de Psiquiatria

Volumn 31, Issue 6, 2003, Pages 347-352

  Navarro Pacheco, B V ^a   Montejo Gonzalez A L ^a   Martin Carrasco M ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Benito Menni Complex Assistencial en Salut Mental   (Spain)

Author keywords

Atypical neuroleptics; Quetiapine; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; HALOPERIDOL; LORAZEPAM; QUETIAPINE; RISPERIDONE;

ADULT; AGED; BIPOLAR DISORDER; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; JEALOUS DELUSION; MAINTENANCE THERAPY; MALE; MENTAL DISEASE; PARANOID SCHIZOPHRENIA; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCORING SYSTEM; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA, PARANOID;

EID: 0347477993     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kane JM, Lieberman JA. Tardive dyskinesia. En: Kane JM, Lieberman JA, editores. Adverse effects of psychotropic drugs. New York: The Guilford Press, 1992, p. 235-45.
2. Jeste DV, Caliguri MP, Paulsen JS, et al. Tardive dyskinesia. Schizophr Bull 1993;19:305-15.
3. García Rivera C. La discinesia tardía, hoy. Primera mesa redonda. Simposium: esquizofrenia, más que un misterio, un rompecabezas. Córdoba, 2003.
4. Chari S, Jainer A, Ashley-Smith A, Cleaver M. Quetiapine in tardive dyskinesia. Int J Psych Clin Practice 2001;6:175-7.
5. Uhrbrand L, Faurybye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and ECT. Psychopharmacology 1960;1:408-18.
6. Bazire S. Psychotropic drug directory 2000: a profesionals' pocket hendbook and aide memoire. Dinton: Mark Allen Puclishing, 2000; p. 82.
7. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Barcelona: Ed. Massen, 2002.
9. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18(4):701-5.
10. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
11. American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington: APA.
12. Jeste DV, Caliguri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-65.
13. van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: the Curaçao extrapyramidal syndrome study III. Am J Psychiatry 1998;155:565-7.
14. Tarsy D, Baldessarini RJ. Pharmacologically induced behavioural supersensivity to apomorphine. Nature 1973;245:262-3.
15. Casey DE. Tardive dyskinesia. En: Hirsch SR, Weinberger DR, editores. Schizophrenia. New York: Blackwell Science, 1995; p. 553-65.
16. Carlsson A. Biochemical implications of dopa-induced actions on the central nervous system with particular reference to abnormal movements. En: Barbeau A, McDowell FH, editores. L-dopa and parkinsonism. Philadelphia: Davis, 1990.
17. Soares KVS, Mc Grath JJ, Decks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia Cochrane review. En: The Cochrane Library, Issue 1 Oxford: Update Software, 2003.
18. Soares KVS, McGrath JJ. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. (Cochrane review). En: The Cochrane Library, Issue 1. Oxford: Update Software, 2003.
19. Soares KVS, Mc Grath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia (Cochrane review). En: The cochrane Library, Issue 1. Oxford: Update Software, 2003.
20. McGrath JJ, Soares-Weiser KVS. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. (Cochrane review). En: The cochrane Library, Issue 1. Oxford: Update Software, 2003.
21. McGrath JJ, Soares KVS. Benzodiazepines for neuroleptic-induced tardive dyskinesia (Cochrane review). En: The cochrane Library, Issue 1. Oxford: Update Software, 2003.
22. Soares KVS, Mc Grath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia (Cochrane review). En: The cochrane Library, Issue 1. Oxford: Update Software, 2003.
23. Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser KVS. Cholinergic medication for neuroleptic-induced tardive dyskinesia (Cochrane review). En: The cochrane Library, Issue 1. Oxford: Update Software, 2003.
24. McGrath JJ, Soares-Weiser KVS. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia (Cochrane review). En: The cochrane Library, Issue 1. Oxford: Update Software, 2003.
25. Casey DE. Tardive dyskinesia. En: Meltzer H, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987; p. 1411-9.
26. Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 1989;25:57-62.
27. Agarwal V, Kumaz P. Olanzapine in treatment of tardive dyskinesia: a report of two cases. J Clin Psychiatry 2001;62:298-9.
28. Chong SA, Remington G, Tan CH. Olanzapine in treatment of tardive dyskinesias: a report of two cases. J Clin Psychiatry 1999;62:298-9.
29. Esel E, Turan MT, Gönül AS. Improvement of tardive dyskinesia in a bipolar patient with olanzapine. Eur Psychiatry 2000;15:438-9.
30. Taminga CA, Thaker GK, Moran M, Kakigu T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(Suppl B):102-6.
31. a ed. Ed. Panamericana, 1999.
32. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-92.
33. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993;112:299-307.
34. Borison RL, Arvanitis LA, Miller BG, Link CGG, Hong WW. Seroquel (ICI 204 636): a novel atypical antipsychotic. Biol Psychiatry 1995;37:661.
35. Wetzel H, Szegedi A, Hain C, Wiesner J, Schegel S, Benkert O. Seroquel (ICI 204 636), a putative «atypical» antypsichotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changer of neuroendocrinological and EEG parameters. Psychopharmacology 1995;119:231-8.
36. Küfferle B, Tauscher K, Asenbaum S, Vesely C, Podrecka I, Brücke T, Kasper S. IBZM SPECT imaging of striatal dopamine-2 receptors in psichotic patients treated with the novel antispychotic substance quetiapine in comparision to clozapine and haloperidol. Psychopharmacology 1997;133:323-8.
37. Brücke T, Roth J, Podreka I, Strobl R, Wenger S, Asenbaum S. Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 1992;339:497.
38. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49(7):538-44.
39. Nyberg S, Farde L, Erikson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 1993;112:285-92.
40. Klemm E, Grünwald F, Kasper S, Menzel C, Boich K, Danos P, et al. (123I)IBZM-SPECT for imaging of striatal D2 dopaminereceptors in 56 schizophrenic patients taking various neuroleptics. Am J Psychiatry 1996;153:183-90.
41. Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry 1999;156:796A-7.
42. Ghaemi SN, Ko JY. Quetiapine-related tardive dyskinesia. Am J Psychiatry 2001;158:173.
43. Alptekin K, Kvrck BB. Quetiapine induced improvement of tardive dyskinesia in three patients with schizophrenia (case report). Int Clin Psychopharmacol 2002;17(5):263-4.
44. Farah A. Reduction of tardive dyskinesia with quetiapine [Letter] Schizophr Res 2001;47(2-3):309-10.
45. Vesely C, Küfferle B, Brücke T, Kasper S. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 2000;15(1):57-60.
46. Meats P. Quetiapine (seroquel): an effective and well tolerated atypical, 1997.
47. Lieberman JA, Salz BL, John CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
48. Navarro B, Montejo AL, Martín M. Quetiapina en el manejo de las discinesias tardías. Simposium: esquizofrenia, mas que un misterio un rompecabezas. Córdoba, 2003.